Researchers described gut microbiota and metabolic alterations common to metabolic syndrome (MetS) and sleep disorders.
Biopharma firm Zetagen raises $9.79m in Series B financing round
In preclinical research, Zetagen’s ZetaMAST showed potential to stop lesion growth. Credit: Zetagen. Clinical-stage biopharma firm Zetagen Therapeutics has raised $9.79m in a Series B